Enzymatic Biotransformation of Ginsenoside Rb1 and Gypenoside XVII into Ginsenosides Rd and F2 by Recombinant β-glucosidase from Flavobacterium johnsoniae

Hao Hong¹², Chang-Hao Cui¹³, Jin-Kwang Kim¹, Feng-Xie Jin², Sun-Chang Kim¹³, and Wan-Taek Im¹*

¹KAIST Institute for Biocentury, Korea Advanced Institute of Science and Technology, Daejeon 305-701, Korea
²College of Biotechnology, Dalian Polytechnic University, Dalian 116034, China
³Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon 305-701, Korea

This study focused on the enzymatic biotransformation of the major ginsenoside Rb1 into Rd for the mass production of minor ginsenosides using a novel recombinant β-glucosidase from Flavobacterium johnsoniae. The gene (bglF3) consisting of 2,235 bp (744 amino acid residues) was cloned and the recombinant enzyme overexpressed in Escherichia coli BL21(DE3) was characterized. This enzyme could transform ginsenoside Rb₁ and gypenoside XVII to the ginsenosides Rd and F2, respectively. The glutathione S-transferase (GST) fused BglF3 was purified with GST-bind agarose resin and characterized. The kinetic parameters for β-glucosidase had apparent $K_m$ values of 0.91±0.02 and 2.84±0.05 mM and $V_{max}$ values of 5.75±0.12 and 0.71±0.01 μmol·min⁻¹·mg of protein⁻¹ against p-nitrophenyl-β-D-glucopyranoside and Rb₁, respectively. At optimal conditions of pH 6.0 and 37°C, BglF3 could only hydrolyze the outer glucose moiety of ginsenoside Rb1 and gypenoside XVII at the C-20 position of aglycon into ginsenosides Rd and F2, respectively. These results indicate that the recombinant BglF3 could be useful for the mass production of ginsenosides Rd and F2 in the pharmaceutical or cosmetic industry.

Keywords: Panax ginseng, Biotransformation, β-glucosidase, Ginsenoside F2, Flavobacterium johnsoniae

INTRODUCTION

Ginseng (Panax ginseng Meyer) has been used as a celebrated traditional herbal medicine to cure diseases and promote health in the Orient for thousands of years [1,2]. Ginsenosides can be categorized into the tetracyclic triterpenoid saponins, including protopanaxadiol (PPD) and protopanaxatriol, and the pentacyclic triterpenoid saponins. The PPD-type ginsenosides are further classified by the position and number of sugar moieties attached by a glycosidic bond to the aglycon at positions C-3 and C-20 [3]. After oral intake of ginseng, the major ginsenosides are hydrolyzed through human intestinal digestion into the more active minor ginsenosides, which are easily absorbed. For instance, ginsenoside Rb1 is converted to ginsenosides Rd, F2, compound K, and aglycon by intestinal microflora [4-6]. Therefore, converting the major ginsenosides, which account for more than 80% of the total ginsenosides, to highly active minor ginsenosides has much significance for the pharmaceutical industry.

Ginsenosides, the major active constituents of ginseng, have various biological and pharmacological activities, including anti-cancer effects [7], anti-inflammatory activity [8], and neuro-protective effects [9]. Ginsen-
osides Rd and F2 have several pharmaceutical functions such as anti-tumor and anti-cancer effects, curing ath-
erosclerosis, neuro-protective effects [10-13], and so on. The minor ginsenosides can be produced by hydrolyzing
sugar moieties from the major ginsenosides [14]. To date, several methods to produce pure ginsenosides such
as heating, acid treatment, and enzymatic methods have been developed. The enzymatic methods are considered
as the most promising approach with advantages of fewer byproducts, superior environmental protection, and
better stereo-specificity [15]. In particular, the purified recombinant enzymes exhibit higher selectivity and
efficiency than those isolated and purified from cultured microorganisms [16].

In this study, we report the cloning of a new gene encoding ginsenoside-hydrolyzing β-glucosidase (BglF3)
from Flavobacterium johnsoniae, followed by expression in Escherichia coli and characterization of β-glucosidase
(BglF3). BglF3 belongs to glycoside hydrolase family 3, and the recombinant enzyme hydrolyzed only the outer
glucose moiety at the C-20 position of ginsenoside Rb1 and gypenoside XVII, which are effectively converted to
ginsenosides Rd and F2, respectively.

MATERIALS AND METHODS

Chemicals

Ginsenosides Rb1, Rb2, Re, Rd, Re, Rg1, Rg3(S), F2, and C-K were purchased from Nanjing Zelang Medical
Technology Co., Ltd. (Nanjing, China) and gypenoside XVII was obtained by our group as described by An et
al. [17]. All the chemicals used in this study were at least analytical reagent grade, and the sources are noted indi-
vidually in the methods section.

Bacterial strains, vectors, and media

F. johnsoniae KACC 11414T, used as a source for cloning of β-glucosidase gene, was cultured on R2A agar
(BD, Sparks, MD, USA) under an aerobic condition at 30°C. E. coli BL21 (DE3) and pGEX 4T-1 plasmid (GE
Healthcare, Waukesha, WI, USA) for gene cloning and expression were cultured in a Luria–Bertani (LB) me-

Cloning, expression, and purification of recombi-
nant BglF3

Genomic DNA of F. johnsoniae KACC 11414T was extracted by using a genomic DNA extraction kit
(Solgent, Daejeon, Korea). The gene, termed bglF3, encoding β-glucosidase (GenBank accession number
ABQ03809) was amplified by polymerase chain reaction (PCR) with Pfu DNA polymerase (Solgent) using the fol-
lowing primers (with BamHI and XhoI restriction sites in boldface): bglF3F (5’-CGGGATCCAAAAACAAATA-
GATATACCTTTCTGC-3’) and bglF3R (5’-CCCCTC-GAGTTATTTAATTGTGAAGTTAATTTCC-3’). The amplified
fragment was digested with BamHI and XhoI and then inserted to the pGEX 4T-1 vector to generate a glutathione S-transferase (GST)-bglF3 gene fusion. E. coli BL21 (DE3), transformed with recombinant
pGEX-bglF3, was grown in LB-ampicillin medium at 37°C until the culture reached an OD600 of 0.6, at which
point protein expression was induced by adding 0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG). Bacteria
were incubated additionally for 24 h at 18°C and then harvested by centrifuging at 10,000 × rpm for 20 min at
4°C. The cells were washed twice with 50 mM sodium phosphate buffer (pH 7.0) and then suspended in 50 mM sodium phosphate buffer (pH 7.0). The cells were disrupted by ultrasonication (Vibra-
cell; Sonics & Materials, Newtown, CT, USA) and the intact cells and debris were removed by centrifugation at
12,000 × rpm for 20 min at 4°C. The GST-tagged fusion protein was purified by GST-bind agarose resin (Elpis-
biootech Co., Daejeon, Korea). The GST tag was removed from the GST-bind agarose resin after being incubated
with thrombin. The homogeneity of the protein was as-

Enzyme characterization and determination of ki-
netic parameters

The specific activity of purified BglF3 was determined by using p-nitrophenyl-β-D-glucopyranoside (PNPG) as
substrate in 50 mM sodium phosphate buffer (pH 6.0) at 37°C. The release of p-nitrophenol was immediately
measured using a microplate reader at 405 nm (Model
680; Bio-Rad, Hercules, CA, USA). One unit of activity
was defined as the amount of protein required to gener-
ate 1 μmol of p-nitrophenol per minute. To check the
optimum condition for the specific enzyme activity, pH,
temperature, metals and chemical reagents were inves-
tigated as previously described [17]. Substrate prefer-
ence was examined by using chromogenic o-nitrophenyl
(ONP) and p-nitrophenyl (PNP). Kinetic studies were
performed with freshly purified enzyme using PNPG and
Rb1 at concentrations ranging from 0.1 mM to 5 mM.
All enzyme assays were performed with triplicate. The

http://ginsengres.org

419
parameters ($K_m$ and $V_{max}$) were determined as described by Wang et al. [3].

**Enzymatic hydrolysis of ginsenosides**

To investigate the biotransformation ability of recombinant β-glucosidase, BglF3, 9 different ginsenosides (Rb1, Rb2, Rc, Rd, Gypenoside XVII, Rg3(S), Re, Rg1, and F2) were evaluated as substrates. The initial biotransformation experiments using ginsenoside Rb1 as the substrate revealed that GST fused with BglF3 did not affect the activities of BglF3. Each ginsenoside was reacted with fused protein solution (0.2 mg/mL in 50 mM sodium phosphate buffer, pH 6.0) with same ratio (1:1, v/v) at 37°C. Also, the hydrolyzing capacity of BglF3 (0.2 mg/mL) was determined by using 1.0, 2.5, and 5.0 mg/mL Rb1 as a substrate in 50 mM sodium phosphate buffer (pH 6.0) at 37°C. Samples were withdrawn at regular intervals. An equal volume of water-saturated n-butanol was added to stop the reaction, and the reactant present in the n-butanol fraction was analyzed by TLC after pretreatment.

**Analysis of ginsenosides by thin-layer chromatography**

TLC was performed using 60F254 silica gel plates (Merck, Darmstadt, Germany) with CHCl3-CH3OH-H2O (65:35:10, v/v, lower phase) in solvent system. The spots on the TLC plates were detected through spraying with 10% (vol/vol) H2SO4, followed by heating at 110ºC for 5 min.

**RESULTS AND DISCUSSION**

**Cloning, expression, and purification of recombinant BglF3**

The β-glucosidase gene consisting of 2,235 bp encoding 744 amino acids, which have homology to the protein domain of glycoside hydrolase family 3, was amplified by PCR and then inserted into the pGEX 4T-1 vector. The GST-BglF3 fusion gene was expressed in E. coli BL21 (DE3) followed by the induction of 0.1 mM IPTG and incubated at 18°C for 24 h. The GST-BglF3 fusion protein was purified by GST-bind agarose resin and then the GST tag was removed by thrombin at room temperature during a 12 h incubation period. The predictive molecular mass (81.8 KDa) of the BglF3 was determined by SDS-PAGE (Fig. 1).

**Enzyme characterization**

BglF3 was active over a broad pH range (pH 4.0 to 9.0) at 37°C. The optimal pH was pH 6.0 in sodium phosphate buffer (Fig. 2A). The enzyme activity retained more than 80% of its optimal activity from pH 5.0 to 8.0, while above pH 10.0 enzyme activity decreased up to 95% and at pH 4.0 the enzyme activity decreased to 30%. The β-glucosidase from Paecilomyces Bainier sp. 229 [18], Thermus caldophilus [19], and Microbacterium esteraromaticum [20] had optima at pH 3.5, 5.0, and 7.0, respectively. The optimal temperature for BglF3 activity was 37°C and the enzyme was stable at lower than 37°C. The enzyme lost 35% of its activity at 45°C, while no thermostability was determined at 55°C (Fig. 2B). However, the purified β-glucosidase from Paecilomyces Bainier sp. 229 [18], T. caldophilus [19], and Sulfolobus solfataricus [21] had the optimal temperatures of 55°C, 75°C, and 90°C, respectively.

The effects of metal ions, EDTA, β-mercaptoethanol, and sodium dodecyl-sulfate (SDS) on BglF3 activity were investigated (Table 1). BglF3 activity was not affected by dithiothreitol or β-mercaptoethanol, which is a well-known thiol group inhibitor. Na+, K+, or Mg2+ had positive effects on the activity of the enzyme while the enzyme activity was inhibited in the presence of both 1 mM and 10 mM Mn2+, Co2+, Zn2+, Ca2+, Cu2+, or Hg2+. The chelating agents EDTA and SDS also inhibited BglF3 activity.

The substrate specificity of BglF3 was tested using 2.0 mM of PNP and ONP-glycosides with α and β configurations (total 17 kinds), as reported previously.
BglF3 was maximally active against PNP-β-D-glucopyranoside, followed by ONP-β-D-glucopyranoside (53.2% compared to PNP-β-D-glucopyranoside), and other substrates were not hydrolyzed. This explained why BglF3 did not have catalytic activity against ginsenoside Rb2 and Rc, which had an outer arabinose moiety at the C-20 position of aglycon. The kinetic parameters for recombinant BglF3 had apparent $K_m$ values of 0.91±0.02 and 2.84±0.05 mM and $V_{max}$ values of 5.75±0.12 and 0.71±0.01 μmol·min$^{-1}$·mg of protein$^{-1}$ against p-nitrophenyl-β-D-glucopyranoside and Rb1, respectively.

**Biotransformation of ginsenosides**

For a thorough investigation of ginsenoside transfor-
mation by recombinant BglF3. 9 ginsenosides (Rb1, Rb2, Rc, Rd, gypenoside XVII, Rg3(S), Re, Rg1, and F2) were used as substrates and recombinant BglF3 could hydrolyze only ginsenoside Rb1 and gypenoside XVII. The hydrolysates of ginsenoside Rb1 and gypenoside XVII were examined at regular intervals by TLC. Ginsenoside Rb1 (1 mg/mL) and gypenoside XVII (1 mg/mL) were completely converted into ginsenosides Rd and F2 after 1.5 h and 4 h, respectively, and no further production occurred during longer reaction time (Fig. 3). This conversion speed was faster than that obtained with the usage of crude enzymes extracts from Paecilomyces sp. 229-7 [22] and Bifidobacterium sp. SH5 [23], which converted 1 mg/mL of ginsenoside Rb1 to Rd within 24 h. These results indicated that BglF3 showed substrate specificity for ginsenoside Rb1 and gypenoside XVII, which had glucose moieties at the C-3 and C-20 positions, and showed specific affinity to only the outer C-20 glucose moiety (Fig. 4). To evaluate the usage of BglF3 at an industrial scale, a high concentration of ginsenosides Rb1 was used as the substrate. BglF3 could wholly hydrolyze 2.5 and 5.0 mg/mL of the ginsenosides Rb1 into Rd within 20 and 72 h, respectively (Fig. 5). Thus, it would be a very practical tool to prepare a large amount of ginsenoside Rd with high-yield if a purified ginsenoside mixture (Rb1, Rc, and Rd) is used as the substrate.

Theoretically, β-glucosidase can hydrolyze the outer and inner glucoses attached to ginsenosides at the C-3 and C-20 positions in various transformation pathways. With regard to glycoside hydrolase family 3, where BglF3 is included, there have been several reports on ginsenoside conversion. For example, Bgp A derived from Terrabacter ginsenosidimutans Gsoil 3082 prefers...
entially hydrolyzed the outer glucose moiety at the C-3 position followed by the inner glucose moiety to make gypenoside XVII and gypenoside LXXV and further into compound K by hydrolyzing the C-20 glucose moiety [17]. Bgp1 derived from *M. esteraromaticum* preferentially hydrolyzed both the outer and inner glucose moieties at the C-20 position until ginsenoside Rg3 was produced finally [24]. The other enzyme, β-glucosidase from *Cladosporium cladosporioides*, converted gypenoside XVII into ginsenoside F2 by hydrolyzing the outer glucose at the C-20 position and further into compound K by hydrolyzing the C-3 glucose moiety [25]. However, in this study, BglF3 could selectively hydrolyze only one outer glucose at the C-20 position for the major ginsenoside Rb1 and gypenoside XVII.

In conclusion, we have constructed recombinant β-glucosidase (BglF3) from *F. johnsoniae* KACC 11414 for biotransformation of ginsenoside Rb1 and gypenoside XVII to more pharmacologically active ginsenosides Rd and F2, respectively, by selectively hydrolyzing their outer glucose moiety at the C-20 position. Optimal reaction conditions for the enzyme are 37°C and pH 6.0. The recombinant BglF3 provides effective ginsenoside Rb1 transformation with high productivity. Therefore, BglF3 would offer a shortcut to prepare ginsenosides Rd and F2 in large-scale industrial production.

**ACKNOWLEDGEMENTS**

This work was supported by a grant from the Next-Generation BioGreen 21 Program (no. PJ008193), Rural Development Administration, and by the Intelligent Synthetic Biology Center of Global Frontier Project funded by the Ministry of Education, Science and Technology (2011-0031967), Republic of Korea.

**REFERENCES**

1. Ernst E. *Panax ginseng*: An overview of the clinical evidence. J Ginseng Res 2010;34:259-263.
2. Kim MH, Lee YC, Choi SY, Cho CW, Rho J, Lee KW. The changes of ginsenoside patterns in red ginseng processed by organic acid impregnation pretreatment. J Ginseng Res 2011;35:497-503.
3. Wang L, Liu QM, Sung BH, An DS, Lee HG, Kim SG, Kim SC, Lee ST, Im WT. Bioconversion of ginsenosides Rb1, Rb2, Re and Rd by novel β-glucosidase hydrolyzing outer 3-O glycoside from *Sphingomonas* sp. 2F2: cloning, expression, and enzyme characterization. J Biotechnol 2011;156:125-133.
4. Wang DM, Yu HS, Song JG, Xu YF, Jin FX. Enzyme kinetics of ginsenoside type IV hydrolyzing 6-O-methylglycosides of protopanaxatriol type ginsenosides. Process Biochem 2012;47:133-138.
5. Tawab MA, Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration. Drug Metab Dispos 2003;31:1065-1071.
6. Akao T, Kida H, Kanaoka M, Hattori M, Kobashi K. Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from *Panax ginseng*. J Pharm Pharmacol 1998;50:1155-1160.
7. Kim HS, Lee EH, Ko SR, Choi JK, Park JH, Im DS. Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells. Arch Pharm Res 2004;27:429-435.
8. Keum YS, Han SS, Chun KS, Park KK, Park JH, Lee SK, Surh YJ. Inhibitory effects of the ginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2 expression, NF-kappaB activation and tumor promotion. Mutat Res 2003;523-524:75-85.
9. Kim S, Nah SY, Rhim H. Neuroprotective effects of ginseng saponins against L-type Ca$^{2+}$ channel-mediated cell death in rat cortical neurons. Biochem Biophys Res Commun 2008;365:399-405.
10. Shin JY, Lee JM, Shin HS, Park SY, Yang JE, Cho SK, Yi TH. Anti-cancer effect of ginsenoside F2 against glioblastoma multiforme in xenograft model in SD rats. J Ginseng Res 2012;36:86-92.
11. Guan YY, Zhou JG, Zhang Z, Wang GL, Cai BX, Hong L, Qiu QY, He H. Ginsenoside-Rd from *Panax notoginseng* blocks Ca$^{2+}$ influx through receptor- and store-operated Ca$^{2+}$ channels in vascular smooth muscle cells. Eur J Pharmacol 2006;548:129-136.
12. Lee JK, Choi SS, Lee HK, Han KJ, Han EJ, Suh HW. Effects of ginsenoside Rd and decursinol on the neurotoxic responses induced by kainic acid in mice. Planta Med 2003;69:230-234.
13. Yang ZG, SunHX, Ye YP. Ginsenoside Rd from *Panax notoginseng* is cytotoxic towards HeLa cancer cells and induces apoptosis. Chem Biodivers 2006;3:187-197.
14. Cheng LQ, Na JR, Kim MK, Bang MH, Yang DC. Microbial conversion of ginsenoside Rb1 to minor ginsenoside F2 and gypenoside XVII by *Intrasporangium* sp. GS603 isolated from soil. J Microbiol Biotechnol 2007;17:1937-1943.
15. Park CS, Yoo MH, Noh KH, Oh DK. Biotransformation of ginsenosides by hydrolyzing the sugar moieties of ginsenosides using microbial glycosidases. Appl Microbiol Biotechnol 2010;87:9-19.
16. Kim BN, Yeom SJ, Kim YS, Oh DK. Characterization of a β-glucosidase from *Sulfolobus solfataricus* for isoflavone glycosides. Biotechnol Lett 2012;34:125-129.

17. An DS, Cui CH, Lee HG, Wang L, Kim SC, Lee ST, Jin F, Yu H, Chin YW, Lee HK et al. Identification and characterization of a novel *Terrabacter ginsenosidimitans* sp. nov. beta-glucosidase that transforms ginsenoside Rb1 into the rare gypenosides XVII and LXXV. Appl Environ Microbiol 2010;76:5827-5836.

18. Yan Q, Zhou W, Li X, Feng M, Zhou P. Purification method improvement and characterization of a novel ginsenoside-hydrolyzing beta-glucosidase from *Paecilomyces Bainier* sp. 229. Biosci Biotechnol Biochem 2008;72:352-359.

19. Son JW, Kim HJ, Oh DK. Ginsenoside Rd production from the major ginsenoside Rb1 by beta-glucosidase from *Thermus caldophilus*. Biotechnol Lett 2008;30:713-716.

20. Quan LH, Min JW, Sathiayamoorthy S, Yang DU, Kim YJ, Yang DC. Biotransformation of ginsenosides Re and Rg1 into ginsenosides Rg2 and Rh1 by recombinant β-glucosidase. Biotechnol Lett 2012;34:913-917.

21. Noh KH, Son JW, Kim HJ, Oh DK. Ginsenoside compound K production from ginseng root extract by a thermostable beta-glycosidase from *Sulfolobus solfataricus*. Biosci Biotechnol Biochem 2009;73:316-321.

22. Ye L, Zhou CQ, Zhou W, Zhou P, Chen DF, Liu XH, Shi XL, Feng MQ. Biotransformation of ginsenoside Rb1 to ginsenoside Rd by highly substrate-tolerant *Paecilomyces Bainier* 229-7. Biocatal Biotransform 2010;101:7872-7876.

23. Chi H, Ji GE. Transformation of ginsenosides Rb1 and Re from *Panax ginseng* by food microorganisms. Biotechnol Lett 2005;27:765-771.

24. Quan LH, Min JW, Yang DU, Kim YJ, Yang DC. Enzymatic biotransformation of ginsenoside Rb1 to 20(S)-Rg3 by recombinant β-glucosidase from *Microbacterium esteraromaticum*. Appl Microbiol Biotechnol 2012;94:377-384.

25. Wu L, Jin Y, Yin C, Bai L. Co-transformation of *Panax* major ginsenosides Rb1 and Rg1 to minor ginsenosides C-K and F1 by *Cladosporium cladosporioides*. J Ind Microbiol Biotechnol 2012;39:521-527.